Top

Published in:

Open Access 01-05-2018 | Original Communication

Smoking at time of CIS increases the risk of clinically definite multiple sclerosis

Authors: Roos M. van der Vuurst de Vries, Julia Y. Mescheriakova, Tessel F. Runia, Theodora A. M. Siepman, Beatrijs H. A. Wokke, Johnny P. A. Samijn, Rogier Q. Hintzen

Published in: Journal of Neurology | Issue 5/2018

Abstract

Background

Cigarette smoking is a modifiable risk factor that influences the disease course of patients with multiple sclerosis (MS). However, in patients with a clinically isolated syndrome (CIS), there are conflicting results about the association between smoking and the risk of a subsequent MS diagnosis. The aim of this study was to determine the risk of clinically definite MS (CDMS) in smoking and non-smoking patients at time of a first demyelinating event.

Methods

Two hundred and fifty patients, aged 18–50 years, were included in our prospective CIS cohort. At time of the first neurological symptoms, patients completed a questionnaire about smoking habits. Cox regression analyses were performed to calculate univariate and multivariate hazard ratios for CDMS diagnosis in smoking and non-smoking CIS patients.

Results

One hundred and fourteen (46%) CIS patients were diagnosed with CDMS during a mean follow-up of 58 months. In total, 79 (32%) patients smoked at time of CIS. Sixty-seven % of the smoking CIS patients were diagnosed with CDMS during follow-up compared to 36% of the non-smoking CIS patients (p < 0.001). Smoking at time of CIS was an independent predictor for CDMS diagnosis (HR 2.3; p = 0.002). Non-smoking CIS patients who had a history of smoking did not have a higher risk for CDMS than those who had never smoked.

Conclusions

Smoking at time of CIS was an independent risk factor for a future CDMS diagnosis. This is an additional argument to quit smoking at time of the first attack of suspected MS.

Compston A, Coles A (2008) Multiple sclerosis. Lancet 372(9648):1502–1517CrossRefPubMed

Huynh JL, Casaccia P (2013) Epigenetic mechanisms in multiple sclerosis: implications for pathogenesis and treatment. Lancet Neurol 12(2):195–206CrossRefPubMedPubMedCentral

Frischer JM, Bramow S, Dal-Bianco A et al (2009) The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132(Pt 5):1175–1189CrossRefPubMedPubMedCentral

Hedstrom AK, Hillert J, Olsson T, Alfredsson L (2013) Smoking and multiple sclerosis susceptibility. Eur J Epidemiol 28(11):867–874CrossRefPubMedPubMedCentral

Handel AE, Williamson AJ, Disanto G et al (2011) Smoking and multiple sclerosis: an updated meta-analysis. PLoS One 6(1):e16149CrossRefPubMedPubMedCentral

Hedstrom AK, Baarnhielm M, Olsson T, Alfredsson L (2011) Exposure to environmental tobacco smoke is associated with increased risk for multiple sclerosis. Mult Scler 17(7):788–793CrossRefPubMed

Hernan MA, Jick SS, Logroscino G et al (2005) Cigarette smoking and the progression of multiple sclerosis. Brain 128(Pt 6):1461–1465CrossRefPubMed

Ramanujam R, Hedstrom AK, Manouchehrinia A et al (2015) Effect of smoking cessation on multiple sclerosis prognosis. JAMA Neurol 72(10):1117–1123CrossRefPubMed

Manouchehrinia A, Tench CR, Maxted J et al (2013) Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study. Brain 136(Pt 7):2298–2304CrossRefPubMedPubMedCentral

10.

Tanasescu R, Constantinescu CS, Tench CR, Manouchehrinia A (2017) Smoking cessation and the reduction of disability progression in Multiple Sclerosis: a cohort study. Nicotine Tob Res. https://doi.org/10.1093/ntr/ntx084

11.

Hedstrom AK, Sundqvist E, Baarnhielm M et al (2011) Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis. Brain 134(Pt 3):653–664CrossRefPubMed

12.

Hedstrom AK, Bomfim IL, Barcellos LF et al (2014) Interaction between passive smoking and two HLA genes with regard to multiple sclerosis risk. Int J Epidemiol 43(6):1791–1798CrossRefPubMedPubMedCentral

13.

Miller DH, Chard DT, Ciccarelli O (2012) Clinically isolated syndromes. Lancet Neurol 11(2):157–169CrossRefPubMed

14.

Arikanoglu A, Shugaiv E, Tuzun E, Eraksoy M (2013) Impact of cigarette smoking on conversion from clinically isolated syndrome to clinically definite multiple sclerosis. Int J Neurosci 123(7):476–479CrossRefPubMed

15.

Di Pauli F, Reindl M, Ehling R et al (2008) Smoking is a risk factor for early conversion to clinically definite multiple sclerosis. Mult Scler 14(8):1026–1030CrossRefPubMed

16.

Correale J, Farez MF (2015) Smoking worsens multiple sclerosis prognosis: two different pathways are involved. J Neuroimmunol 281:23–34CrossRefPubMed

17.

Munger KL, Fitzgerald KC, Freedman MS et al (2015) No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT. Neurology 85(19):1694–1701CrossRefPubMedPubMedCentral

18.

Horakova D, Zivadinov R, Weinstock-Guttman B et al (2013) Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study. PLoS One 8(1):e53996CrossRefPubMedPubMedCentral

19.

Miller DH, Weinshenker BG, Filippi M et al (2008) Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 14(9):1157–1174CrossRefPubMedPubMedCentral

20.

Schumacher GA, Beebe G, Kibler RF et al (1965) Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci 122:552–568CrossRefPubMed

21.

Poser CM, Paty DW, Scheinberg L et al (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13(3):227–231CrossRefPubMed

22.

Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452CrossRefPubMed

23.

Versini M, Tiosano S, Comaneshter D et al (2017) Smoking and obesity in systemic lupus erythematosus: a cross-sectional study. Eur J Clin Invest 47(6):422–427CrossRefPubMed

24.

Stolt P, Bengtsson C, Nordmark B et al (2003) Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann Rheum Dis 62(9):835–841CrossRefPubMedPubMedCentral

25.

Degelman ML, Herman KM (2017) Smoking and multiple sclerosis: a systematic review and meta-analysis using the Bradford Hill criteria for causation. Mult Scler Relat Disord 17:207–216CrossRefPubMed

26.

Kappos L, Polman CH, Freedman MS et al (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67(7):1242–1249CrossRefPubMed

27.

Tintore M, Rovira A, Rio J et al (2015) Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain 138(Pt 7):1863–1874CrossRefPubMed

28.

Sayao AL, Devonshire V, Tremlett H (2007) Longitudinal follow-up of “benign” multiple sclerosis at 20 years. Neurology 68(7):496–500CrossRefPubMed

29.

Munger KL, Chitnis T, Ascherio A (2009) Body size and risk of MS in two cohorts of US women. Neurology 73(19):1543–1550CrossRefPubMedPubMedCentral

30.

Dare S, Mackay DF, Pell JP (2015) Relationship between smoking and obesity: a cross-sectional study of 499,504 middle-aged adults in the UK general population. PLoS One 10(4):e0123579CrossRefPubMedPubMedCentral

31.

Hedstrom AK, Hillert J, Olsson T, Alfredsson L (2014) Alcohol as a modifiable lifestyle factor affecting multiple sclerosis risk. JAMA Neurol 71(3):300–305CrossRefPubMed

32.

Shiffman S, Hufford M, Hickcox M et al (1997) Remember that? A comparison of real-time versus retrospective recall of smoking lapses. J Consult Clin Psychol 65(2):292–300CrossRefPubMed

33.

Arnson Y, Shoenfeld Y, Amital H (2010) Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 34(3):J258–J265CrossRefPubMed

Title: Smoking at time of CIS increases the risk of clinically definite multiple sclerosis
Authors: Roos M. van der Vuurst de Vries
Julia Y. Mescheriakova
Tessel F. Runia
Theodora A. M. Siepman
Beatrijs H. A. Wokke
Johnny P. A. Samijn
Rogier Q. Hintzen
Publication date: 01-05-2018
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 5/2018
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-018-8780-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Smoking at time of CIS increases the risk of clinically definite multiple sclerosis

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2018

Within-patient fluctuation of brain volume estimates from short-term repeated MRI measurements using SIENA/FSL

Movement disorders in mitochondrial disease

[18F] AV-1451 uptake in corticobasal syndrome: the influence of beta-amyloid and clinical presentation

The Dizziness Handicap Inventory does not correlate with vestibular function tests: a prospective study

Short- and long-term clinical outcomes of use of beta-interferon or glatiramer acetate for people with clinically isolated syndrome: a systematic review of randomised controlled trials and network meta-analysis

Mild cognitive impairment in Parkinson’s disease: the Parkinson’s disease cognitive study (PACOS)